Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- Basking Ridge, Commack, Miami, Middletown, New York, and Uniondale, United StatesSee the 6 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 103 people enrolled
- Started
- 24 Dec 2020
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Craniotomy
- Cesium-131 brachytherapy
- Record updated
- 4 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Adult patients ≥ 18 years of age who are capable of giving consent
- Undergoing elective craniotomy for resection of a previously-irradiated brain metastasis with suspicion for viable disease at the time of consent, and anticipated achievement of gross-total or near-total (>/=95%) resection
- Karnofsky Performance Status score (KPS) of ≥70
- Ability to undergo brain MRI with gadolinium
Who cannot take part
- Prior irradiation (EQD2) in excess of 100 Gy to site of implant, using an α/β of 2
- Previous infection within the operative field, current active systemic infection requiring systemic therapy, or immunodeficiency
- Urgent surgery required prior to availability of brachytherapy; Intraoperative Exclusion Criterion:
- Patients will be excluded if intraoperative pathology is not consistent with >/=5% viable metastatic disease
- Unable to tolerate MRI or CT imaging
- Pregnancy (patients must have a negative pregnancy test within 30 days of the operation)
- Women must agree to not breastfeed for at least 12 weeks after the procedure (lactating and discarding in that interval allowable)
- Diagnosis of leptomeningeal carcinomatosis or >5 additional active or untreated CNS lesions for a total of >6 active lesions
- Apposition of tumor margin to brainstem or optic apparatus
Where in United States
- Memorial Sloan Kettering at Basking Ridge (Consent Only)Basking Ridge, United States
- Memorial Sloan Kettering Commack (Consent only)Commack, United States
- Baptist Health South FloridaMiami, United States
- Memorial Sloan Kettering Monmouth (Consent Only)Middletown, United States
- Memorial Sloan-Kettering Cancer CenterNew York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale, United States
About the trial
What the trial wants to find out
The purpose of this study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after surgery.The researchers will compare Cs-131 brachytherapy (which occurs during brain surgery) with the usual approach of brain surgery without brachytherapy. The researchers will compare both the effectiveness and safety of the two approaches.
The 2 groups in the trial
- Resection without brachytherapyExisting treatment, for comparison
Patients will undergo craniotomy.
Treatment: Craniotomy
- Resection plus brachytherapyTreatment being tested
Patients will undergo craniotomy and patients in the treatment arm will undergo implantation of Cesium 131 brachytherapy in coordination with the radiation oncologist.
Treatment: Craniotomy and Cesium-131 brachytherapy
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 4 June 2026